Biopharm shuts its doors

By staff reporter

- Last updated on GMT

Related tags Pharmacology

New Zealand-owned drug maker Biopharm will shut its doors after
running out of money.

The facility, a subsidiary of Industrial Research, had been manufacturing, among other things, cytotoxins – cancer-killing drugs – for international pharma firms, however it was bleeding badly. "After several years spent manufacturing a range of products for pharmaceutical companies, Biopharm was no longer economically viable,"​ said Industrial Research chief executive Shaun Coffey. "Efforts to attract investment in these new initiatives weren't successful, and Industrial Research wasn't in a position to continue operations or develop the business further."​ All twenty-eight staff will lose their jobs unless other positions can be found for them within Industrial Research, although this part of the business itself has already been downsizing of late, slashing 71 jobs last year.

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us

Products

View more

Webinars